Pancreatic cancer: Conservative and adjuvant therapy;PANKREASKARZINOM: KONSERVATIVE UND ADJUVANTE THERAPIE

Therapeutische Umschau

Volumn 53, Issue 5, 1996, Pages 387-393

  Schmassmann, A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BUPRENORPHINE; DIAZEPAM; DOXORUBICIN; FLUOROURACIL; FLUOXETINE; KREON; METOCLOPRAMIDE; MITOMYCIN; MITOMYCIN MEDAC; MORPHINE; OMEPRAZOLE; PANCREATIN; STREPTOZOCIN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; ORAL DRUG ADMINISTRATION; PANCREAS CARCINOMA; SHORT SURVEY; SYMPTOMATOLOGY; VOMITING;

AGED; ANALGESIA; COMBINED MODALITY THERAPY; DIET; HUMANS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 0029994064     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (20)

1. Aoki Y., Kolsumi M.: Palliative surgery for unresectable carcinoma of the pancreas ampulla and distal end of common bile duct in Japan. A statistical review. Am. J. Surg. 147, 349-353, 1984.
2. Warshaw A. L., Fernández-del Castillo C.: Pancreatic carcinoma. N. Engl. J. Med. 326, 455-456, 1992.
3. Gudjonsson B., Livstone E. M., Spiro H. M.: Cancer of the pancreas: diagnostic accuracy and survival statistics. Cancer 42, 2494-2506, 1978.
4. Cameron J. L., Crist D. W., Sitzmann J. V. et al.: Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am. J. Surg. 161, 120-125, 1991.
5. Smith A. C., Dowsett J. F., Russell R. C. G., Hatfield A. R. W., Cotton P. B.: Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 344, 1655-1659, 1994.
6. Watanapa P., Williamson R. C. N.: Surgical palliation for pancreatic cancer: developments during the past two decades. Br. J. Surg. 79, 8-20, 1992.
7. Shepherd H. A., Royle G., Ross A. P., Diba A., Arthur M., Colin-Jones D.: Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomised trial. Br. J. Surg. 75, 1166-1169, 1988.
8. Andersen J. R., Sorensen S. M., Kruse A., Rollaer M., Matzen P.: Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 30, 1132-1135, 1989.
9. Speer A. G., Cotton P. B., Russell R. C., et al.: Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 2, 57-62, 1987.
10. Davids H. P., Groen A. K., Rauws E., Tytgat G., Huibregtse K.: Randomised trial of self-expanding metal stents versus plastic stents for distal malignant biliary obstruction. Lancet 340, 1488-1492, 1992.
11. Sarr M. G., Cameron J. L.: Surgical palliation of unresectable carcinoma of the pancreas. World J. Surg. 8, 906-318, 1984.
12. Ihse I., Andersson R., Axelson J.: Pancreatic pain: is there a medical alternative to surgery. Digestion 54 (Suppl. 2), 30-34, 1993.
13. Matsuno S., Hisano H., Kobari M., Akaishi S.: Growth-inhibitory effects of combination chemotherapy for human pancreatic cancer cell lines. Cancer 66, 2369-2374, 1990.
14. Klijn J. G. M., Hoff A. M., Planting A. S. Th., Verweij J., Kok T., Lamberts S. W. J., Portengen H., Foekens J. A.: Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br. J. Cancer 62, 627-630, 1990.
15. Bakkevold K. E., Petterson A., Arnesjo B., Espehaug B.: Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br. J. Surg. 77, 725-730, 1990.
16. Büchler M., Friess H., Schultheiss K. H., Gebhardt C., Kubel R. et al.: A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 68, 1507-1512, 1991.
17. Moertel C. G., Childs D. S., Reitemeier R. J., Colby M. Y., Holbrook M. C.: Combined 5-fluorouracial and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2, 865-867. 1969.
18. Moertel C. G., Frytak S., Hahn R. G., et al.: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads), radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48, 1705-1710, 1981.
19. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59, 2006-2010, 1987.
20. Ozaki H., Hojo K., Kalo H., Kinoshita T., Egawa S., Kishi K.: Multidisciplinary treatment for resectable pancreatic cancer. Int. J. Pancreatol. 3. 249-260, 1988.